Targeting BTK in CLL: Beyond Ibrutinib
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00512-0
Relapsed T Cell ALL: Current Approaches and New Directions
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00501-3
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00527-7
The Role of PI3K Inhibition in Lymphoid Malignancies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00540-w
Solitary Plasmacytoma: a Review of Diagnosis and Management
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00499-8
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00528-6
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00538-4
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00523-x
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00502-2
Treatment-Free Remission in CML: the US Perspective
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0496-8
IMiDs New and Old
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00536-6
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00508-w
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00545-5
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00511-1
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00543-7
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00525-9
Is There a Role for Dose Modification of TKI Therapy in CML?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00524-w
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0495-9
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00531-x
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00533-9
Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00552-6
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00555-3
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00510-2
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00521-z
Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00516-w
Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00505-z
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00530-y
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0493-y
Overcoming Challenges in Process Development of Cellular Therapies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00529-5
Correction to: Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00506-y
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00556-2
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00518-8
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0494-x
Multi-Specific CAR Targeting to Prevent Antigen Escape
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00537-5
Driving the CAR to the Bone Marrow Transplant Program
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00544-6
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00549-1
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00507-x
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00546-4
Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00542-8
Chromatin-Remodeled State in Lymphoma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00541-9
Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00500-4
Early Management of CML
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00550-8
Development and Significance of Mouse Models in Lymphoma Research
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00504-0
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00553-5
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00526-8
Mutation-Driven Therapy in MDS
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00554-4
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00519-7
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0492-z
Towards Automated Manufacturing for Cell Therapies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00522-y
The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00547-3